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BRIEF REPORT

Implementation of a medical student‑run
telemedicine program for medications
for opioid use disorder during the COVID‑19
pandemic
Marcus Castillo1, Brianna Conte1, Sam Hinkes1, Megan Mathew1, C. J. Na1, Ainhoa Norindr1, David P. Serota2,
David W. Forrest3, Amar R. Deshpande1, Tyler S. Bartholomew4* and Hansel E. Tookes2

Abstract
Objectives: The COVID-19 pandemic led to the closure of the IDEA syringe services program medical student-run
free clinic in Miami, Florida. In an effort to continue to serve the community of people who inject drugs and practice
compassionate and non-judgmental care, the students transitioned the clinic to a model of TeleMOUD (medications
for opioid use disorder). We describe development and implementation of a medical student-run telemedicine clinic
through an academic medical center-operated syringe services program.
Methods: Students advertised TeleMOUD services at the syringe service program on social media and created an
online sign-up form. They coordinated appointments and interviewed patients by phone or videoconference where
they assessed patients for opioid use disorder. Supervising attending physicians also interviewed patients and prescribed buprenorphine when appropriate. Students assisted patients in obtaining medication from the pharmacy and
provided support and guidance during home buprenorphine induction.
Results: Over the first 9 weeks in operation, 31 appointments were requested, and 22 initial telehealth appointments were completed by a team of students and attending physicians. Fifteen appointments were for MOUD and
7 for other health issues. All patients seeking MOUD were prescribed buprenorphine and 12/15 successfully picked
up medications from the pharmacy. The mean time between appointment request and prescription pick-up was
9.5 days.
Conclusions: TeleMOUD is feasible and successful in providing people who inject drugs with low barrier access to
life-saving MOUD during the COVID-19 pandemic. This model also provided medical students with experience treating addiction during a time when they were restricted from most clinical activities.
Keywords: COVID-19, Telehealth, Medications for opioid use disorder, Student-run clinic
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Introduction
The coronavirus disease 2019 (COVID-19) global pandemic has highlighted inequalities that disproportionately affect marginalized communities, including persons
who inject drugs (PWID) [1, 2]. PWID are more likely
to have chronic medical conditions and experience
homelessness, incarceration, and crowded living conditions compared to the general population, all which
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pose unique challenges regarding the transmission of
the virus. Furthermore, increased stress and anxiety
can worsen mental health comorbidities and lead to an
increase in substance use [3].
The Infectious Disease Elimination Act (IDEA) syringe
services program (SSP) at the University of Miami was
established to improve the health outcomes of PWID by
providing them with sterile injection equipment, naloxone, and improved access to medical care [4]. A free
student-run clinic in collaboration with the Mitchell
Wolfson Sr Department of Community Service (DOCS),
operating out of the IDEA SSP, was developed to meet
the medical needs of participants and create a space to
educate students on the principles of harm reduction.
The clinic’s primary function was to provide primary
and specialty care to PWID, particularly general health
screenings, referrals for medications for opioid use disorder (MOUD), and wound care for skin and soft tissue infections [5]. With the onset of COVID-19, 43% of
SSPs nationally reduced their services and 25% reported
closures [6]. Similarly, the IDEA SSP curtailed its hours
of operation and services, and the on-site clinic was
suspended.
In order to continue serving the local population of
PWID and fostering educational patient interactions,
students conceived and implemented a free virtual clinic
that offers MOUD and addresses general health concerns. The students understood the benefits of this medication after having gone through the University of Miami
Miller School of Medicine opioid education curriculum
that was introduced in 2019 to train and educate all medical students on identifying and treating patients with
substance use disorder. Funded by the Florida Department of Children and Families, the overarching goal
of the grant is to implement a longitudinal curriculum
inclusive of the content of the DATA 2000 waiver training that would enable all graduates to prescribe lifesaving
medications for opioid use disorder.
With the closure of treatment clinics and a focus of
emergency departments on COVID-19 patients during the pandemic [7], the virtual clinic was created with
a dual mission of addressing service gaps while reducing face-to-face clinical interactions and providing students with experience in caring for PWID during these
unprecedented times. Here, we describe the implementation of this student-run free virtual MOUD program
(TeleMOUD) amid the COVID-19 pandemic in Miami,
Florida.

Methods
Human subjects

This study was reviewed by the Institutional Review
Board of the University of Miami (IRB # 20200879).
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Work flow

An online form was created for patients to request virtual
appointments for MOUD, and these services were promoted via flyers at the IDEA SSP and on its social media
accounts. Patients who submitted appointment requests
are contacted by a student volunteer to collect paperwork
confirming eligibility for the free clinic, which include
Florida residency and income < 200% of the federal poverty level. An additional student volunteer assisted with
the patient history and case presentation.
The existing clinic electronic health record (EHR) was
updated with the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) criteria for the
diagnosis of opioid use disorder (OUD), and a modified
Clinical Opiate Withdrawal Scale (COWS) [8] focused
on the subjective symptoms of withdrawal. Appointments began with two students interviewing the patient
through a remote videoconference platform or by phone.
The students then discussed the case with the attending
and re-connected with the patient as a group to complete
the visit. The attending was responsible for checking the
prescription drug monitoring program to evaluate for
concurrent controlled substance prescriptions. Initially,
paper MOUD prescriptions were provided, but this
process was updated to electronic prescribing or phoning MOUD prescriptions to a mutually agreed upon
pharmacy.
Students helped counsel patients on the logistics of
buprenorphine induction and assisted patients as they
went through the process. All patients started on MOUD
had formal follow-up appointments scheduled within
2 weeks of initiation, every 2 weeks after that for 6 weeks,
and thereafter every 4 weeks. Students remained in frequent contact with patients early in their treatment.
Medication efficacy, craving management, and side
effects were discussed and dosing titrated to desired
effect by the physician.
Statistical analysis

Data were collected retrospectively from the online
appointment request system and clinic EHR. Frequency
distributions for categorical variables and medians and
interquartile ranges (IQR) were presented to describe the
overall study sample. To understand the time intervals
of the TeleMOUD care cascade, we calculated the mean
number of days between steps.

Results
TeleMOUD care cascade

Between March 30, 2020, and June 08, 2020, 31 requests
were made for telehealth services at the student clinic. Of
these, 22 appointments were completed; reasons for the 9
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Fig. 1 TeleMOUD care cascade. The steps between appointment request, completion of appointment, and follow-ups are displayed in descending
boxes. Boxes on the right provide details on services provided or reasons for falling out of the care cascade. The mean number of days between
each step is presented. *Of those who dropped out from MOUD dispensed to follow-up appointment, one person entered the hospital for
behavioral and mental health services, and one person was lost to follow up
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non-completed appointments are described in Fig. 1. Of
the patients with completed appointments, 15 (68%) were
prescribed buprenorphine; 12 of 15 (80%) successfully
picked up their prescription for buprenorphine at the
pharmacy, and 10 of 12 (83%) completed their first follow-up visit. The average time from appointment request
to receipt of medications was 9.5 days (Fig. 1).
Characteristics of patients

The median age of patients was 35.5 years (Table 1), and
the largest proportion of patients were white non-Hispanic (43%) and male (67%). Of the 15 patients seeking
MOUD, 5 were currently injecting drugs, 2 used opioids by non-injection routes, 7 were refilling their prescription or changing providers, and 1 was already not
currently using. Reasons for transition to TeleMOUD
included temporary closure of treatment centers due to
COVID-19, convenience of telehealth treatment, and dissatisfaction with their current provider.

Table 1 Descriptive statistics of those accessing telehealth
during COVID-19 (N = 22)
Characteristic

N (%)

Age (median, IQR)

35.5 (33–51)

Biological sex
Male
Female

14 (67)
7 (33)

Race/ethnicity
White non-Hispanic

9 (43)

Black non-Hispanic

4 (19)

Hispanic

8 (38)

IDEA SSP participant
Yes

11 (52)

No

10 (48)

Current injection drug use
Yes

10 (50)

No

10 (50)

Substances injected (n = 10)
Heroin

8 (80)

Fentanyl

5 (50)

Cocaine

2 (20)

Other (ketamine)

1 (10)

Self-reported HIV status
Positive

3 (14)

Negative

16 (76)

Unknown

2 (10)

Self-reported HCV status
Positive

8 (38)

Negative

10 (48)

Unknown

3 (14)

Discussion
In this descriptive study, we demonstrate the feasibility of
rapid implementation of a student-run free TeleMOUD
program housed within an academic medical centeroperated SSP. Despite multiple studies demonstrating
the association of MOUD with reduced morbidity and
mortality [9, 10], access to MOUD remains limited in the
USA, with 96% of states reporting higher rates of opioid
use than buprenorphine treatment capacity [11]. Due to
the COVID-19 pandemic, this already limited access to
MOUD was further impeded due to the closure of opioid treatment clinics and the prioritization of COVID-19
patients in hospital emergency departments [7].
Sexual Health Care Clinics and SSPs provided examples on how to connect patients with providers during
COVID-19 via telehealth [12, 13], and a recent opinion
paper demonstrated the utility of telehealth in preventing
disruption of care for people with OUD and co-occurring
mental health disorders during COVID-19 [14]. With the
development of TeleMOUD, we aimed to mitigate disruptions in care by serving patients with OUD who could not
receive in person care within a hospital or clinic setting.
Additionally, we sought to provide medical students, who
were mostly restricted from direct clinical care during
the early stages of the pandemic, important experience
treating patients with OUD while responding to a public
health crisis.
There is a growing body of evidence demonstrating
the utility of using telemedicine technology for treating OUD [15]. However, before the pandemic, adoption of telehealth for OUD had been limited by policies
that required face-to-face interactions and monitoring of patients, technological challenges for patients
and providers, and clinicians’ concerns about a negatively impacted doctor–patient relationship [16]. During the pandemic, TeleMOUD was possible because the
Drug Enforcement Agency allowed for the initiation of
buprenorphine treatment via telemedicine. Students
proved key in helping to address technological issues by
creating online appointment request forms, promoting
the clinic via the SSP’s social media pages, and helping
participants to sign forms virtually and access video conferencing apps. Providers and patients expressed great
satisfaction with TeleMOUD, and the patients who saw
a psychiatrist or mental health counselor, in conjunction
with or following their MOUD provider, described this as
a benefit.
Lack of medication availability at patient’s local
pharmacies proved a challenge to both patients and
providers, and this was a barrier to care. Cost of medication was a common concern for many patients, and
students worked closely with them to obtain coupons
that increased affordability. As a result of continuous
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process improvement efforts, we have now partnered
with a pharmacy at a nearby safety-net healthcare system operating a 340B Drug Pricing Program that offers
patients significant discounts irrespective of insurance
status.
TeleMOUD became possible because Drug Enforcement Agency requirements for a face-to-face visit for
the initiation of care and the prescription of controlled
substances were lifted during the pandemic. Whereas
we attempted to use videoconferencing technology
for all visits, many of the patients served did not have
access to appropriate technology and their visits were
completed over the phone; reinstatement of the face-toface requirement would pose a significant barrier to this
model. Furthermore, the waiver of urine drug screens
under the SAMHSA guidelines allowed us to rapidly
implement this low barrier path to care initiation [17];
rules requiring urine drug screen for initiation of care
should remain waived as an unnecessary burden to
buprenorphine initiation. For insured patients, removal
of onerous prior authorization requirements catalyzed
rapid progress to a low-threshold MOUD model.
The implementation of a substance use disorder curriculum provided students with the knowledge to pursue
and develop the TeleMOUD clinic, serve marginalized
populations during the pandemic, and practice harm
reduction. While it is too early to draw conclusions on
the community impact of TeleMOUD, early evidence
supports the implementation of a more robust Tele-Harm
Reduction model at SSPs. Adapting educational protocols
for telehealth across undergraduate medical education
can illuminate to students the benefits and limitations of
this technology, encourage innovation for the delivery of
care, and prepare them to respond to future health crises.
The policy changes that allowed these services to commence created new possibilities to reduce morbidity and
mortality from preventable overdose among PWID, and
it is our hope that beyond the COVID-19 era we will not
forfeit the progress made during this pandemic.
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